文献速递临床试验与 GCP基础与转化研究

BRAF突变黑色素瘤中持续与间歇BRAF/MEK抑制的随机2期试验

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
PubMed 文献 · Nat Med · 2020-10-05

S1320是一项随机开放标签2期试验,评估间歇与持续达拉非尼联合曲美替尼对BRAF V600突变不可切除或转移性黑色素瘤无进展生存期的影响。206例患者经8周持续导入后按1:1随机,持续组中位随机后无进展生存期9.0个月,间歇组5.5个月(P=0.064,预设双侧α=0.2),间歇给药未改善无进展生存期,总生存和治疗相关毒性总体发生率无差异。

要点

  • 间歇BRAF/MEK抑制未改善BRAF突变黑色素瘤的无进展生存期。
  • 持续组中位随机后无进展生存期9.0个月,间歇组5.5个月。
  • 两组总生存和治疗相关毒性总体发生率无差异。

核心结论

  • 与初始假设相反,间歇给予达拉非尼和曲美替尼未改善BRAF V600突变黑色素瘤患者的无进展生存期。

研究设计与样本

  • S1320为随机、开放标签、2期临床试验(NCT02196181),在全国68个学术和社区中心入组患者。
  • 所有患者先接受8周持续达拉非尼和曲美替尼导入,无进展者随机接受持续或间歇给药(停3周、服5周)。
  • 206例基线特征相似的患者按1:1随机,105例持续给药,101例间歇给药。

主要发现

  • 持续给药组随机后无进展生存期中位9.0个月,间歇给药组5.5个月(P=0.064,预设双侧α=0.2)。
  • 总生存和治疗相关毒性总体发生率等次要结局在两组间无差异。

关键数值与推荐

  • 随机后无进展生存期:持续组中位9.0个月,间歇组中位5.5个月,P=0.064,预设双侧α=0.2。

临床怎么用

  • 对于BRAF V600突变不可切除或转移性黑色素瘤,间歇BRAF/MEK抑制策略未显示无进展生存获益,不支持以间歇给药替代持续给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whether intermittent dosing of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib improves progression-free survival in patients with metastatic and unresectable BRAFV600 melanoma. Patients were enrolled at 68 academic and community sites nationally. All patients received continuous dabrafenib and trametinib during an 8-week lead-in period, after which patients with non-progressing tumors were randomized to either continuous or intermittent dosing of both drugs on a 3-week-off, 5-week-on schedule. The trial has completed accrual and 206 patients with similar baseline characteristics were randomized 1:1 to the two study arms (105 to continuous dosing, 101 to intermittent dosing). Continuous dosing yielded a statistically significant improvement in post-randomization progression-free survival compared with intermittent dosing (median 9.0 months versus 5.5 months, P = 0.064, pre-specified two-sided α = 0.2). Therefore, contrary to the initial hypothesis, intermittent dosing did not improve progression-free survival in patients. There were no differences in the secondary outcomes, including overall survival and the overall incidence of treatment-associated toxicity, between the two groups.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Algazi AP, Othus M, Daud AI, et al. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020. PMID: 33020646. doi:10.1038/s41591-020-1060-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。